Advertisement

Tumor Biology

, Volume 36, Issue 3, pp 1619–1625 | Cite as

Investigation of microRNA-155 as a serum diagnostic and prognostic biomarker for colorectal cancer

  • Zhong-chuan Lv
  • Yong-sheng Fan
  • Hong-bing Chen
  • Da-wei Zhao
Research Article

Abstract

The aim of the present study was to explore serum microRNA-155 (miR-155) expression in patients with colorectal cancer (CRC) and examined the potential usefulness of this molecule as a biomarker for diagnosis and prognosis in CRC. Serum samples were obtained between May 2007 and March 2013 from 146 CRC patients and 60 healthy controls. Serum miR-155 expression levels were measured by quantitative real time reverse transcription-polymerase chain reaction (qRT-PCR). Survival curves were obtained using the Kaplan–Meier method and assessed by the log-rank test. The receiver operating characteristic (ROC) curve was used for the prediction of cut-off values of the markers. Serum miR-155 expression level on average was upregulated in CRC patients compared with the matched healthy controls (P < 0.001). ROC curve analysis showed that miR-155 was a useful marker for discriminating cases from healthy controls, with an area under the ROC curve (AUC) of 0.776 (95 % confidence interval (CI) 0.714 to 0.837, P < 0.001). Kaplan–Meier analysis with the log-rank test indicated that high serum miR-155 expression had a significant impact on overall survival (38.2 vs. 69.9 %; P < 0.001) and progression-free survival (34.8 vs. 66.0 %; P < 0.001). In conclusion, the detection of miR-155 levels in the serum might serve as a new tumor biomarker in the diagnosis and assessment of prognosis of CRC.

Keywords

Colorectal cancer miR-155 Noninvasive biomarker Prognostic marker Diagnostic marker 

Notes

Conflicts of interest

None

References

  1. 1.
    Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014;64(1):9–29.CrossRefPubMedGoogle Scholar
  2. 2.
    Tan E, Gouvas N, Nicholls RJ, Ziprin P, Xynos E, Tekkis PP. Diagnostic precision of carcinoembryonic antigen in the detection of recurrence of colorectal cancer. Surg Oncol. 2009;18(1):15–24.CrossRefPubMedGoogle Scholar
  3. 3.
    Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer. What you should know. Oncol (Williston Park). 2006;20(6):579–87. discussion 588, 594, 596 passim.Google Scholar
  4. 4.
    Schetter AJ, Leung SY, Sohn JJ, Zanetti KA, Bowman ED, Yanaihara N, et al. MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA : J Am Med Assoc. 2008;299(4):425–36.CrossRefGoogle Scholar
  5. 5.
    Lu J, Getz G, Miska EA, Alvarez-Saavedra E, Lamb J, Peck D, et al. MicroRNA expression profiles classify human cancers. Nature. 2005;435(7043):834–8.CrossRefPubMedGoogle Scholar
  6. 6.
    Calin GA, Croce CM. MicroRNA signatures in human cancers. Nat Rev Cancer. 2006;6(11):857–66.CrossRefPubMedGoogle Scholar
  7. 7.
    Calin GA, Sevignani C, Dumitru CD, Hyslop T, Noch E, Yendamuri S, et al. Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A. 2004;101(9):2999–3004.CrossRefPubMedPubMedCentralGoogle Scholar
  8. 8.
    Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704–14.CrossRefPubMedPubMedCentralGoogle Scholar
  9. 9.
    Jurkovicova D, Magyerkova M, Kulcsar L, Krivjanska M, Krivjansky V, Gibadulinova A, et al. miR-155 as a diagnostic and prognostic marker in hematological and solid malignancies. Neoplasma. 2014;61(3):241–51.CrossRefPubMedGoogle Scholar
  10. 10.
    Li H, Xie S, Liu M, Chen Z, Liu X, Wang L, et al. The clinical significance of downregulation of mir-124-3p, mir-146a-5p, mir-155-5p and mir-335-5p in gastric cancer tumorigenesis. Int J Oncol. 2014;45(1):197–208.PubMedGoogle Scholar
  11. 11.
    Shi LJ, Zhang CY, Zhou ZT, Ma JY, Liu Y, Bao ZX, Jiang WW (2014) MicroRNA-155 in oral squamous cell carcinoma: overexpression, localization, and prognostic potential. Head & NeckGoogle Scholar
  12. 12.
    Xu TP, Zhu CH, Zhang J, Xia R, Wu FL, Han L, et al. MicroRNA-155 expression has prognostic value in patients with non-small cell lung cancer and digestive system carcinomas. Asian Pac J Cancer Prev: APJCP. 2013;14(12):7085–90.CrossRefPubMedGoogle Scholar
  13. 13.
    Kong W, Yang H, He L, Zhao JJ, Coppola D, Dalton WS, et al. MicroRNA-155 is regulated by the transforming growth factor beta/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA. Mol Cell Biol. 2008;28(22):6773–84.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Li T, Yang J, Lv X, Liu K, Gao C, Xing Y, Xi T (2014) miR-155 regulates the proliferation and cell cycle of colorectal carcinoma cells by targeting E2F2. Biotechnology LettersGoogle Scholar
  15. 15.
    Zhang GJ, Xiao HX, Tian HP, Liu ZL, Xia SS, Zhou T. Upregulation of microRNA-155 promotes the migration and invasion of colorectal cancer cells through the regulation of claudin-1 expression. Int J Mol Med. 2013;31(6):1375–80.PubMedGoogle Scholar
  16. 16.
    Shibuya H, Iinuma H, Shimada R, Horiuchi A, Watanabe T. Clinicopathological and prognostic value of microRNA-21 and microRNA-155 in colorectal cancer. Oncology. 2010;79(3–4):313–20.CrossRefPubMedGoogle Scholar
  17. 17.
    Ng EK, Chong WW, Jin H, Lam EK, Shin VY, Yu J, et al. Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut. 2009;58(10):1375–81.CrossRefPubMedGoogle Scholar
  18. 18.
    Porkka KP, Pfeiffer MJ, Waltering KK, Vessella RL, Tammela TL, Visakorpi T. MicroRNA expression profiling in prostate cancer. Cancer Res. 2007;67(13):6130–5.CrossRefPubMedGoogle Scholar
  19. 19.
    Akao Y, Nakagawa Y, Naoe T. MicroRNA-143 and -145 in colon cancer. DNA Cell Biol. 2007;26(5):311–20.CrossRefPubMedGoogle Scholar
  20. 20.
    Mo MH, Chen L, Fu Y, Wang W, Fu SW. Cell-free circulating miRNA biomarkers in cancer. J Cancer Educ. 2012;3:432–48.CrossRefGoogle Scholar
  21. 21.
    Chen X, Ba Y, Ma L, Cai X, Yin Y, Wang K, et al. Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res. 2008;18(10):997–1006.CrossRefPubMedGoogle Scholar
  22. 22.
    Taylor DD, Gercel-Taylor C. MicroRNA signatures of tumor-derived exosomes as diagnostic biomarkers of ovarian cancer. Gynecol Oncol. 2008;110(1):13–21.CrossRefPubMedGoogle Scholar
  23. 23.
    Toiyama Y, Hur K, Tanaka K, Inoue Y, Kusunoki M, Boland CR, et al. Serum miR-200c is a novel prognostic and metastasis-predictive biomarker in patients with colorectal cancer. Ann Surg. 2014;259(4):735–43.CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    Chen J, Wang W, Zhang Y, Chen Y, Hu T. Predicting distant metastasis and chemoresistance using plasma miRNAs. Med Oncol. 2014;31(1):799.CrossRefPubMedGoogle Scholar
  25. 25.
    Sun Y, Wang M, Lin G, Sun S, Li X, Qi J, et al. Serum microRNA-155 as a potential biomarker to track disease in breast cancer. PLoS One. 2012;7(10):e47003.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Gao F, Chang J, Wang H, Zhang G. Potential diagnostic value of miR-155 in serum from lung adenocarcinoma patients. Oncol Rep. 2014;31(1):351–7.PubMedGoogle Scholar
  27. 27.
    Tan ZQ, Liu FX, Tang HL, Su Q. [Expression and its clinical significance of hsa-miR-155 in serum of endometrial cancer]. Zhonghua fu chan ke za zhi. 2010;45(10):772–4.PubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2014

Authors and Affiliations

  • Zhong-chuan Lv
    • 1
  • Yong-sheng Fan
    • 2
  • Hong-bing Chen
    • 1
  • Da-wei Zhao
    • 1
  1. 1.Department of Gastrointestinal SurgeryYantai Yuhuangding HospitalYantaiChina
  2. 2.Department of General SurgeryQixia People’s HospitalYantaiChina

Personalised recommendations